Sanofi to acquire UK biotechnology firm Vicebio for up to $1.6bn
The deal will enhance Sanofi's vaccine development capabilities through Vicebio's 'Molecular Clamp' technology.

A leading resource for the Pharmaceutical industry since 2002
The deal will enhance Sanofi's vaccine development capabilities through Vicebio's 'Molecular Clamp' technology.
Give your business an edge with our leading industry insights.
Chemspec Europe 2025 returns to Cologne with expanded exhibition space, enhanced digital tools, and a diverse line-up of industry leaders. This premier event will showcase cutting-edge solutions across key sectors,...
Seal the deal
Excipient evolution shaping pharma innovation
Solving the EDDO guidance puzzle
AI-driven delivery